Inhibrx, Inc. (NASDAQ:INBX) Director Buys $996,748.68 in Stock

Inhibrx, Inc. (NASDAQ:INBXGet Free Report) Director Jon Faiz Kayyem bought 57,549 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were acquired at an average cost of $17.32 per share, with a total value of $996,748.68. Following the purchase, the director now directly owns 1,150,410 shares of the company’s stock, valued at approximately $19,925,101.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Inhibrx Stock Up 2.5 %

Shares of NASDAQ INBX traded up $0.41 on Friday, reaching $16.65. 343,871 shares of the company’s stock traded hands, compared to its average volume of 456,184. Inhibrx, Inc. has a 12 month low of $15.25 and a 12 month high of $18.95. The business’s 50 day simple moving average is $32.33 and its two-hundred day simple moving average is $32.96. The company has a market cap of $872.49 million, a price-to-earnings ratio of -3.31 and a beta of 2.87. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 17.68.

Institutional Investors Weigh In On Inhibrx

A number of institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. grew its holdings in shares of Inhibrx by 22.6% during the third quarter. RA Capital Management L.P. now owns 4,724,207 shares of the company’s stock valued at $86,689,000 after buying an additional 870,340 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Inhibrx by 1.0% in the third quarter. Vanguard Group Inc. now owns 1,789,811 shares of the company’s stock worth $32,843,000 after purchasing an additional 18,271 shares during the last quarter. Vestal Point Capital LP purchased a new stake in Inhibrx in the fourth quarter worth approximately $58,140,000. PFM Health Sciences LP boosted its holdings in Inhibrx by 86.4% in the fourth quarter. PFM Health Sciences LP now owns 537,964 shares of the company’s stock worth $20,443,000 after purchasing an additional 249,347 shares during the last quarter. Finally, MMCAP International Inc. SPC purchased a new stake in Inhibrx in the first quarter worth approximately $15,782,000. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Inhibrx Company Profile

(Get Free Report)

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

See Also

Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.